Mammalian sterile 20‑like kinase 1 expression and its prognostic significance in patients with breast cancer

Lin,Xiao‑Yan; Cai,Feng‑Feng; Wang,Ming‑Hong; Pan,Xin; Wang,Fang; Cai,Lu; Cui,Rong‑Rong; Chen,Su; Biskup,Ewelina

doi:10.3892/ol.2017.6852

Mammalian sterile 20‑like kinase 1 expression and its prognostic significance in patients with breast cancer

Authors:
- Xiao‑Yan Lin
- Feng‑Feng Cai
- Ming‑Hong Wang
- Xin Pan
- Fang Wang
- Lu Cai
- Rong‑Rong Cui
- Su Chen
- Ewelina Biskup
View Affiliations

Affiliations: Department of Breast Surgery, Yangpu Hospital, Tongji University School of Medicine, Shanghai 200090, P.R. China, Department of Cardiology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, P.R. China, Central Laboratory, Yangpu Hospital, Tongji University School of Medicine, Shanghai 200090, P.R. China, Department of Pharmacy, Yangpu Hospital, Tongji University School of Medicine, Shanghai 200090, P.R. China, Department of Molecular and Cellular Biology, School of Forensic Sciences, Xi'an Jiao Tong University Health Science Center, Xi'an, Shaanxi 710061, P.R. China, Department of Internal Medicine, University Hospital of Basel, Basel 4031, Switzerland
Published online on: August 28, 2017 https://doi.org/10.3892/ol.2017.6852
Pages: 5457-5463
Copyright: © Lin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mammalian sterile 20‑like kinase 1 (Mst1) is a major inhibitor of cell proliferation, and is involved in apoptosis, oncogenesis and organ growth via its ubiquitously encoded serine threonine kinase. Previous studies have demonstrated that Mst1 has a tumor suppressor function in human breast cancer. Mst1 deletion or mutation is associated with tumorigenesis, whereas Mst1 overexpression leads to tumor cell apoptosis and decreases proliferation of tumor cells. Our previous study reported the tumor suppressive function of Mst1, and debated Mst1 as a prognostic factor in human breast cancer. In the present study, Mst1 levels were measured in the plasma of patients in order to elucidate their association with overall and disease‑free survival. The results of the present study indicated that Mst1 is a strong prognostic and predictive factor in human breast cancer and a promising anticancer target.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
4	Swanton C, Burrell RA and Futreal PA: Breast cancer genome heterogeneity: A challenge to personalised medicine? Breast Cancer Res. 13:1042011. View Article : Google Scholar : PubMed/NCBI
5	Jackson SE and Chester JD: Personalised cancer medicine. Int J Cancer. 137:262–266. 2015. View Article : Google Scholar : PubMed/NCBI
6	Tyrer J, Duffy SW and Cuzick J: A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 23:1111–1130. 2004. View Article : Google Scholar : PubMed/NCBI
7	Yersal O and Barutca S: Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol. 5:412–424. 2014. View Article : Google Scholar : PubMed/NCBI
8	Garg M, Nagpal N, Sidhu DS and Singh A: Effect of lump size and nodal status on prognosis in invasive breast cancer: Experience from Rural India. J Clin Diagn Res. 10:PC08–PC11. 2016.PubMed/NCBI
9	Senkus E, Cardoso F and Pagani O: Time for more optimism in metastatic breast cancer? Cancer Treat Rev. 40:220–228. 2014. View Article : Google Scholar : PubMed/NCBI
10	Marmé F and Schneeweiss A: Personalised therapy in breast cancer. Onkologie. 35 Suppl 1:S28–S33. 2012. View Article : Google Scholar
11	Andersen SL, Terry DF, Wilcox MA, Babineau T, Malek K and Perls TT: Cancer in the oldest old. Mech Ageing Dev. 126:263–267. 2005. View Article : Google Scholar : PubMed/NCBI
12	Lichtman SM: Guidelines for the treatment of elderly cancer patients. Cancer Control. 10:445–453. 2003. View Article : Google Scholar : PubMed/NCBI
13	Baird RD and Caldas C: Genetic heterogeneity in breast cancer: The road to personalized medicine? BMC Med. 11:1512013. View Article : Google Scholar : PubMed/NCBI
14	Sabatier R, Gonçalves A and Bertucci F: Personalized medicine: Present and future of breast cancer management. Crit Rev Oncol Hematol. 91:223–233. 2014. View Article : Google Scholar : PubMed/NCBI
15	Dawson SJ, Rueda OM, Aparicio S and Caldas C: A new genome-driven integrated classification of breast cancer and its implications. EMBO J. 32:617–628. 2013. View Article : Google Scholar : PubMed/NCBI
16	Ellsworth RE, Decewicz DJ, Shriver CD and Ellsworth DL: Breast cancer in the personal genomics era. Curr Genomics. 11:146–161. 2010. View Article : Google Scholar : PubMed/NCBI
17	Dancey JE, Bedard PL, Onetto N and Hudson TJ: The genetic basis for cancer treatment decisions. Cell. 148:409–420. 2012. View Article : Google Scholar : PubMed/NCBI
18	André F, Bachelot T, Commo F, Campone M, Arnedos M, Dieras V, Lacroix-Triki M, Lacroix L, Cohen P, Gentien D, et al: Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: A multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol. 15:267–274. 2014. View Article : Google Scholar : PubMed/NCBI
19	Song H, Mak KK, Topol L, Yun K, Hu J, Garrett L, Chen Y, Park O, Chang J, Simpson RM, et al: Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci USA. 107:1431–1436. 2010. View Article : Google Scholar : PubMed/NCBI
20	Qin F, Tian J, Zhou D and Chen L: Mst1 and Mst2 kinases: Regulations and diseases. Cell Biosci. 3:312013. View Article : Google Scholar : PubMed/NCBI
21	Cinar B, Collak FK, Lopez D, Akgul S, Mukhopadhyay NK, Kilicarslan M, Gioeli DG and Freeman MR: MST1 is a multifunctional caspase-independent inhibitor of androgenic signaling. Cancer Res. 71:4303–4313. 2011. View Article : Google Scholar : PubMed/NCBI
22	Abdollahpour H, Appaswamy G, Kotlarz D, Diestelhorst J, Beier R, Schäffer AA, Gertz EM, Schambach A, Kreipe HH, Pfeifer D, et al: The phenotype of human STK4 deficiency. Blood. 119:3450–3457. 2012. View Article : Google Scholar : PubMed/NCBI
23	Praskova M, Khoklatchev A, Ortiz-Vega S and Avruch J: Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by Ras. Biochem J. 381:453–462. 2004. View Article : Google Scholar : PubMed/NCBI
24	Graves JD, Gotoh Y, Draves KE, Ambrose D, Han DK, Wright M, Chernoff J, Clark EA and Krebs EG: Caspase-mediated activation and induction of apoptosis by the mammalian Ste20-like kinase Mst1. EMBO J. 17:2224–2234. 1998. View Article : Google Scholar : PubMed/NCBI
25	Qin F, Tian J, Zhou D and Chen L: Mst1 and Mst2 kinases: Regulations and diseases. Cell Biosci. 3:312013. View Article : Google Scholar : PubMed/NCBI
26	Rawat SJ, Creasy CL, Peterson JR and Chernoff J: The tumor suppressor Mst1 promotes changes in the cellular redox state by phosphorylation and inactivation of peroxiredoxin-1 protein. J Biol Chem. 288:8762–8771. 2013. View Article : Google Scholar : PubMed/NCBI
27	Guo C, Zhang X and Pfeifer GP: The tumor suppressor RASSF1A prevents dephosphorylation of the mammalian STE20-like kinases MST1 and MST2. J Biol Chem. 286:6253–6261. 2011. View Article : Google Scholar : PubMed/NCBI
28	Warfel NA and Newton AC: Pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP): A new player in cell signaling. J Biol Chem. 287:3610–3616. 2012. View Article : Google Scholar : PubMed/NCBI
29	Artemenko Y, Batsios P, Borleis J, Gagnon Z, Lee J, Rohlfs M, Sanséau D, Willard SS, Schleicher M and Devreotes PN: Tumor suppressor Hippo/MST1 kinase mediates chemotaxis by regulating spreading and adhesion. Proc Natl Acad Sci USA. 109:13632–13637. 2012. View Article : Google Scholar : PubMed/NCBI
30	Lin X, Cai F, Li X, Kong X, Xu C, Zuo X and Yang Q: Prognostic significance of mammalian sterile 20-like kinase 1 in breast cancer. Tumour Biol. 34:3239–3243. 2013. View Article : Google Scholar : PubMed/NCBI
31	Pan X, Zeng SL, Yu DH, Liang XL, Ji CD, Pan BJ, Cai JL, Wang Y, Min Y, Fang W and Liao WQ: Variable domain of the heavy chain of heavy-chain antibody of the Rv0733 antigen of mycobacterium tuberculosis panned and identified from a nonimmune llama VHH phage display library. Int J Clin Exp Pathol. 9:2869–2878. 2016.
32	Yoneda A, Lendorf ME, Couchman JR and Multhaupt HA: Breast and ovarian cancers: A survey and possible roles for the cell surface heparan sulfate proteoglycans. J Histochem Cytochem. 60:9–21. 2012. View Article : Google Scholar : PubMed/NCBI
33	Hirata Banin BK, Oda JM, Guembarovski Losi R, Ariza CB, de Oliveira CE and Watanabe MA: Molecular markers for breast cancer: Prediction on tumor behavior. Dis Markers. 2014:5131582014.PubMed/NCBI
34	Esteva FJ and Hortobagyi GN: Prognostic molecular markers in early breast cancer. Breast Cancer Res. 6:109–118. 2004. View Article : Google Scholar : PubMed/NCBI
35	Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X and Perou CM: Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 12:R682010. View Article : Google Scholar : PubMed/NCBI
36	Kumar R: Breast cancer tumor markers. J Solid Tumors. 2:432012. View Article : Google Scholar
37	Payne SJ, Bowen RL, Jones JL and Wells CA: Predictive markers in breast cancer-the present. Histopathology. 52:82–90. 2008. View Article : Google Scholar : PubMed/NCBI
38	Penault-Llorca F and Viale G: Pathological and molecular diagnosis of triple-negative breast cancer: A clinical perspective. Ann Oncol. 23 Suppl 6:vi19–vi22. 2012. View Article : Google Scholar : PubMed/NCBI
39	Minoo P, Zlobec I, Baker K, Tornillo L, Terracciano L, Jass JR and Lugli A: Prognostic significance of mammalian sterile 20-like kinase 1 in colorectal cancer. Mod Pathol. 20:331–338. 2007. View Article : Google Scholar : PubMed/NCBI
40	Seidel C, Schagdarsurengin U, Blümke K, Würl P, Pfeifer GP, Hauptmann S, Taubert H and Dammann R: Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. Mol Carcinog. 46:865–871. 2007. View Article : Google Scholar : PubMed/NCBI
41	Cinar B, Collak FK, Lopez D, Akgul S, Mukhopadhyay NK, Kilicarslan M, Gioeli DG and Freeman MR: MST1 is a multifunctional caspase-independent inhibitor of androgenic signaling. Cancer Res. 71:4303–4313. 2011. View Article : Google Scholar : PubMed/NCBI
42	Oh HJ, Lee KK, Song SJ, Jin MS, Song MS, Lee JH, Im CR, Lee JO, Yonehara S and Lim DS: Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis. Cancer Res. 66:2562–2569. 2006. View Article : Google Scholar : PubMed/NCBI
43	Lehtinen MK, Yuan Z, Boag PR, Yang Y, Villén J, Becker EB, DiBacco S, de la Iglesia N, Gygi S, Blackwell TK and Bonni A: A conserved MST-FOXO signaling pathway mediates oxidative-stress responses and extends life span. Cell. 125:987–1001. 2006. View Article : Google Scholar : PubMed/NCBI
44	Avruch J, Zhou D, Fitamant J, Bardeesy N, Mou F and Barrufet LR: Protein kinases of the Hippo pathway: Regulation and substrates. Semin Cell Dev Biol. 23:770–784. 2012. View Article : Google Scholar : PubMed/NCBI